Search research articles
Contact Us
Filters
Showing results (721-730 of 754) with videos related to
Page
of 76
Sort By:
NEJM AI
|
July 15, 2026
SmartAlert - Implementing Machine Learning-Driven Clinical Decision Support for Inpatient Laboratory Utilization Reduction
April S Liang, Fatemeh Amrollahi, Yixing Jiang, et al.
Circulation
|
November 19, 2019
Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure
Scott D Solomon, Muthiah Vaduganathan, Brian L Claggett, et al.
European Heart Journal
|
October 28, 2022
Growth differentiation factor 15 and cardiovascular risk: individual patient meta-analysis
Eri Toda Kato, David A Morrow, Jianping Guo, et al.
Heart Failure Reviews
|
February 5, 2015
Site selection for heart failure clinical trials in the USA
Matthew E Harinstein, Javed Butler, Stephen J Greene, et al.
European Heart Journal
|
August 15, 2021
Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction
Alice M Jackson, Pardeep S Jhund, Inder S Anand, et al.
European Journal of Heart Failure
|
November 7, 2023
Sacubitril/valsartan compared to ramipril in high-risk post-myocardial infarction patients stratified according to use of mineralocorticoid receptor antagonists: Insight from the PARADISE MI trial
Morten Schou, Brian Claggett, Zi Michael Miao, et al.
Circulation
|
November 2, 2022
The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI Trial
Roxana Mehran, Philippe Gabriel Steg, Marc A Pfeffer, et al.
European Journal of Heart Failure
|
April 13, 2021
Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics
Karola S Jering, Brian Claggett, Marc A Pfeffer, et al.
European Heart Journal
|
August 9, 2014
New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes
Michele Senni, Walter J Paulus, Antonello Gavazzi, et al.
Pathogens (Basel, Switzerland)
|
September 23, 2022
Genetic Variants of Glucose-6-Phosphate Dehydrogenase and Their Associated Enzyme Activity: A Systematic Review and Meta-Analysis
Daniel A Pfeffer, Ari Winasti Satyagraha, Arkasha Sadhewa, et al.
Page
of 76
Search research articles
Search
Showing results (721-730 of 754) with videos related to
Sort By:
Page
of 76
NEJM AI
|
July 15, 2026
SmartAlert - Implementing Machine Learning-Driven Clinical Decision Support for Inpatient Laboratory Utilization Reduction
April S Liang, Fatemeh Amrollahi, Yixing Jiang, et al.
Circulation
|
November 19, 2019
Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure
Scott D Solomon, Muthiah Vaduganathan, Brian L Claggett, et al.
European Heart Journal
|
October 28, 2022
Growth differentiation factor 15 and cardiovascular risk: individual patient meta-analysis
Eri Toda Kato, David A Morrow, Jianping Guo, et al.
Heart Failure Reviews
|
February 5, 2015
Site selection for heart failure clinical trials in the USA
Matthew E Harinstein, Javed Butler, Stephen J Greene, et al.
European Heart Journal
|
August 15, 2021
Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction
Alice M Jackson, Pardeep S Jhund, Inder S Anand, et al.
European Journal of Heart Failure
|
November 7, 2023
Sacubitril/valsartan compared to ramipril in high-risk post-myocardial infarction patients stratified according to use of mineralocorticoid receptor antagonists: Insight from the PARADISE MI trial
Morten Schou, Brian Claggett, Zi Michael Miao, et al.
Circulation
|
November 2, 2022
The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI Trial
Roxana Mehran, Philippe Gabriel Steg, Marc A Pfeffer, et al.
European Journal of Heart Failure
|
April 13, 2021
Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics
Karola S Jering, Brian Claggett, Marc A Pfeffer, et al.
European Heart Journal
|
August 9, 2014
New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes
Michele Senni, Walter J Paulus, Antonello Gavazzi, et al.
Pathogens (Basel, Switzerland)
|
September 23, 2022
Genetic Variants of Glucose-6-Phosphate Dehydrogenase and Their Associated Enzyme Activity: A Systematic Review and Meta-Analysis
Daniel A Pfeffer, Ari Winasti Satyagraha, Arkasha Sadhewa, et al.
Page
of 76